Tociliuzumab

Phase 2Monoclonal antibody

Roche

Tociliuzumab is one of 40 small molecule programs targeting Takayasu arteritis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Takayasu ArteritisActive, not recruiting

PneumoniaActive, not recruiting

Takayasu ArteritisPreclinical

Active, not recruiting

PneumoniaPhase 2

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Innohep

Alnylam Pharmaceuticals

Preclinical

1 2

Jakafi

Incyte

Preclinical

1 3

Neutrexin

WWest Japan Thoracic Oncology Group

Preclinical

12 4

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

2 5

Zantac 150

CChattem

Preclinical

2 6

Tociliuzumab

Roche

Phase 2

1 7

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 8

Alka-Seltzer

AAbbott

Preclinical

1 9

Pepcid

KKenvue Brands

Preclinical

1 10

Aciphex

Akero Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ARecruiting

Takayasu Arteritis

NCT07491913

Clinical

Trials by Indication[1]

Pneumonia1 trial

A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia

Completed· Roche logo

Roche·Phase 2·NCT04363736·97 enrolled

Takayasu arteritis1 trial

Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission

Recruiting·MMarmara University·N/A·NCT07491913·40 enrolled

Antisynthetase Syndrome1 trial

Tocilizumab for Refractory Anti-Synthetase Syndrome-Associated Interstitial Lung Disease: A Real-World Retrospective Cohort Study

Completed·HHu Yinan··NCT07662265·111 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Tociliuzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tociliuzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tociliuzumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: Roche

Tociliuzumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Pneumonia1 trial

Takayasu arteritis1 trial

Antisynthetase Syndrome1 trial

References

Drug Info

Quick Facts

Related News